Inflammatory Pain

The anti-inflammatory therapeutics market is expected to be valued at around $100billion by 2020 as more people battle through the pain barrier on a daily basis. Inflammation results from tissue injury which initiates the recruitment of immune cells and mediator release. It is the body’s way of initiating the healing process following injury. Inflammation represents a key biological process and, as such, occurs not only in response to infection but also to a diverse range of disease states such as cancer and diabetes. It is well-established that inflammation whether attributable to autoimmunity (e.g. rheumatoid arthritis; RA) or chemical mediators (e.g. gout) causes nociceptive pain.

Acute and chronic inflammatory pain models have been used routinely by the pharmaceutical industry to provide information that helps to guide strategic decision-making around the mechanism of action and efficacy of molecules targeting inflammatory pain as well as providing robust pharmacodynamic end-points.

Examples of the models we offer include:

Examples of end points:

pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

uk flag +44 (0)20 7691 0984

ireland flag +353 (0)1896 42 60



Copyright © 2020 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design


The first International Association for the Study of Pain, (IASP) virtual conference is live!

Come and visit Transpharmation’s booth #iaspvirtualseries

View our latest specialist poster on pain; ‘The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type 1 diabetic rodents’ and find out more about our wide-ranging pain expertise.  We look forward to seeing you there.

IASP Footer